Literature DB >> 21365931

[Effect of obstructive sleep apnea- hypopnea syndrome on hypertension and metabolism disorder].

Wenjun Liu1, Ruifeng Ge, Xubin Mei, Tao He, Qiyi Zhang, Chongqi Jia.   

Abstract

OBJECTIVE: We investigated the influence of obstructive sleep apnea -hypopnea syndrome (OSAHS) on hypertension and metabolism.
METHOD: There were two groups in this research; they were the research group including 115 patients who were diagnosed with polysomnography and the control group of 122 healthy persons. The blood pressure in the morning, plasmas glucose (GLU), total cholesterol (TC), triglyceride (TG), and uric acid (UA) were measured. There were 32 moderate or severe OSAHS patients and 20 healthy persons were selected to be measured the mitochondrial coupling factor 6 (CF6) with radio-immunity method. The results were analyzed with statistic method. The P < 0.05 means the significant difference. RESULT: The patients' blood pressure in the morning was significantly higher than the control healthy persons. The plasmas glucose, total cholesterol, triglyceride, and uric acid of the OSAHS patients were all in a higher level than those of the control group healthy persons. There were significant differences between the two groups. The mitochondrial coupling factor 6 (CF6) of moderate OSAHS patients or severe OSAHS patients was more than that of the healthy persons (P < 0.05).
CONCLUSION: OSAHS is a potential risk factor on the cardiovascular diseases and the metabolism disorders. The mitochondrial coupling factor 6 (CF6) may play an important role in the procedure of X syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21365931

Source DB:  PubMed          Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1001-1781


  1 in total

1.  Association between uric acid levels and obstructive sleep apnea syndrome in a large epidemiological sample.

Authors:  Camila Hirotsu; Sergio Tufik; Camila Guindalini; Diego R Mazzotti; Lia R Bittencourt; Monica L Andersen
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.